Medical Device Reimbursement: Coverage, Coding, and Payment

Introduction

A medical device can have FDA clearance, exceptional clinical data, and strong physician demand, yet fail commercially if payer reimbursement is inadequate. The gap between regulatory clearance and adequate reimbursement is one of the most common reasons device companies underperform revenue expectations. Healthcare bankers evaluating MedTech companies must assess not just the regulatory pathway but the reimbursement strategy: Does a code exist? Does the payment rate cover the device cost? Is the reimbursement permanent or temporary?

Step 1: Coverage

Coverage is the threshold question: will the payer agree to pay for the procedure that uses this device? Coverage decisions are made separately by Medicare (through National Coverage Determinations and Local Coverage Determinations) and by each commercial payer.

Coverage requires clinical evidence that the device is "reasonable and necessary" (Medicare's standard) or "medically necessary" (most commercial payers' standard). A device with strong randomized controlled trial data typically achieves coverage faster than one with observational data or case series.

Step 2: Coding

Coding translates clinical procedures and devices into standardized codes that payers use for claims processing and payment. Three code systems matter for devices:

New Technology Add-on Payment (NTAP)

A Medicare payment mechanism that provides hospitals with additional reimbursement above the standard DRG payment for qualifying new technologies. NTAP applies to technologies that are new (within 2-3 years of FDA market entry), represent a substantial clinical improvement over existing treatments, and have costs that are inadequately covered by the existing DRG payment. The NTAP amount is 65% of the cost exceeding the DRG payment (75% for breakthrough devices). NTAP is temporary, typically lasting 2-3 years until the technology's costs are incorporated into the regular DRG payment calculation. For device companies, NTAP provides a critical bridge between FDA clearance and adequate permanent reimbursement.

Step 3: Payment

Payment is the amount the payer reimburses the hospital for the procedure. The payment rate must cover the hospital's costs (including the device cost, surgeon fees, facility costs, and overhead) with sufficient margin for the hospital to offer the procedure.

Inpatient devices are typically reimbursed under the DRG system, where the hospital receives a fixed payment per discharge regardless of actual costs. If the device cost exceeds what the DRG payment covers, the hospital loses money on each case, creating resistance to adoption.

Outpatient devices are reimbursed under the Outpatient Prospective Payment System (OPPS) through Ambulatory Payment Classifications (APCs). Similar to DRGs, APCs bundle payment for the procedure, and device costs must fit within the APC payment.

For outpatient settings, CMS offers Transitional Pass-Through Payment (TPT) for new devices, drugs, and biologicals. TPT provides separate payment for the device on top of the standard APC payment for 2-3 years. Unlike NTAP (which is a percentage add-on), TPT provides cost-based reimbursement for the device itself, more directly addressing the cost gap.

Devices eligible for TPT must be new (within specific timeframes), not significantly more expensive than the existing standard of care (cost criterion), and represent a substantial clinical improvement.

The final article in this section covers EU MDR and international regulatory divergence, which adds another layer of complexity for global MedTech companies.